Compare TILE & NEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TILE | NEO |
|---|---|---|
| Founded | 1973 | 2001 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Home Furnishings | Precision Instruments |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.2B | 2.1B |
| IPO Year | 1994 | 2008 |
| Metric | TILE | NEO |
|---|---|---|
| Price | $37.42 | $17.84 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 8 |
| Target Price | ★ $36.00 | $13.38 |
| AVG Volume (30 Days) | 477.4K | ★ 1.7M |
| Earning Date | 05-08-2026 | 04-28-2026 |
| Dividend Yield | ★ 0.29% | N/A |
| EPS Growth | ★ 32.43 | N/A |
| EPS | ★ 1.28 | N/A |
| Revenue | ★ $1,386,854,000.00 | N/A |
| Revenue This Year | $6.72 | $10.63 |
| Revenue Next Year | $5.61 | $9.73 |
| P/E Ratio | $28.91 | ★ N/A |
| Revenue Growth | ★ 5.41 | N/A |
| 52 Week Low | $24.40 | $7.07 |
| 52 Week High | $40.50 | $19.76 |
| Indicator | TILE | NEO |
|---|---|---|
| Relative Strength Index (RSI) | 49.56 | 59.50 |
| Support Level | $27.29 | $15.72 |
| Resistance Level | $40.07 | N/A |
| Average True Range (ATR) | 1.08 | 0.75 |
| MACD | -0.36 | 0.00 |
| Stochastic Oscillator | 11.91 | 43.94 |
Interface Inc is engaged in the design, production, and sale of carpet tiles. It also provides Luxury Vinyl tiles and rubber flooring. The company mainly targets corporate and noncorporate office markets, including government, education, healthcare, hospitality, and retailers. Its geographical segments include the Americas, Europe, and Asia-Pacific. It has two operating and reportable segments- namely Americas (AMS) and Europe, Africa, Asia and Australia (collectively EAAA). Key revenue is generated from AMS segment. Its products include: ESD, Acoustic, Extreme Wear, and Quick Installation System (nTx).
NeoGenomics Inc provides oncology diagnostic testing and consultative services which include technical laboratory services and professional interpretation of laboratory test results by licensed physicians or molecular experts in pathology and oncology. The company operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. The company operates in a single segment and derives revenue from clients by providing clinical cancer testing, interpretation, and consultative services, molecular and NGS testing, comprehensive technical and professional services offerings, clinical trials and research, validation laboratory services, and oncology data solutions.